

## Certificate of Analysis for NR-40270

## Monoclonal Anti-Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein, Clone 9D5 (produced *in vitro*)

## Catalog No. NR-40270

This reagent is the property of the U.S. Government.

**Product Description:** Mouse monoclonal antibody prepared against the Crimean-Congo hemorrhagic fever virus (CCHFV) nucleocapsid protein was affinity purified from clone 9D5 hybridoma supernatant using protein G magnetic beads.

Lot: 61506756 Manufacturing Date: 18APR2013

TEST	SPECIFICATIONS	RESULTS
Antibody Class Determination	IgG2ак	IgG2ак
Experion Pro260 Analysis	Correct molecular weight (MW) for heavy and light chains Report results	Correct MW for heavy and light chains 97.9% pure
Concentration by Spectrophotometer at OD <sub>280</sub>	Report results	1.2 mg per mL
Functional Activity <sup>1</sup> Indirect immunofluorescence assay (IFA) titer <sup>2</sup> Plaque reduction neutralization test (PRNT) titers PRNT <sub>50</sub> <sup>3</sup> PRNT <sub>80</sub> <sup>4</sup>	Report results Report results Report results	64000 ≤ 40 ≤ 40
Sterility	0.22 µm filter-sterilized	0.22 µm filter-sterilized

<sup>&</sup>lt;sup>1</sup>Testing performed at U.S. Army Medical Research Institute of Infectious Diseases

**Date:** 13 MAR 2014

Signature:

**Title:** Technical Manager, BEI Authentication or designee

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® and the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>The IFA titer is defined as the reciprocal of the lowest antibody dilution where nucleocapsid staining was clearly visible above background in CCHFV lbAr10200-infected Vero E6 cells.

<sup>&</sup>lt;sup>3</sup>The PRNT<sub>50</sub> is defined as the reciprocal of the antibody dilution required to reduce the number of CCHFV lbAr10200 plaques in Vero E6 cells by 50% relative to the control wells.

<sup>&</sup>lt;sup>3</sup>The PRNT<sub>80</sub> is defined as the reciprocal of the antibody dilution required to reduce the number of CCHFV lbAr10200 plaques in Vero E6 cells by 80% relative to the control wells.